• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on MSCI Inc. (NYSE: MSCI)

    1/17/24 9:00:00 AM ET
    $MSCI
    $RPRX
    $SWI
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MSCI alert in real time by email

    NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management

    Provides Evidence That Each of MSCI's Four Business Segments is Under Pressure, Resulting in Client Retention Challenges

    Expresses Concern That MSCI Uses Aggressive Accounting and Financial Reporting to Place Greater Emphasis on Adjusted EPS While Cash Flow Stagnates and the Dividend Growth Rate Plunges

    Believes MSCI's $949 Million Acquisition of Real Capital Analytics Should be Evaluated for Impairment After Client Losses and Rising Competition

    Observes That MSCI Exhibits a Pattern of Opaque Deal-Making with People and Entities Related to Morgan Stanley and Questions if They are in the Best Interest of Shareholders

    Believes That MSCI – Known for its Environmental, Social and Governance Ratings – Has its Own Social and Governance Deficiencies That Must be Improved

    Sees 55% to 65% Long-Term Downside Risk to MSCI's Share Price and Believes MSCI's Stock Should Be Underweighted Relative to the S&P 500

    Spruce Point Capital Management, LLC ("Spruce Point" or "we" or "us"), a New York-based investment management firm that focuses on forensic research and short-selling, today issued a detailed report entitled "Indexing The Short Case Against MSCI" that outlines why we believe shares of MSCI Inc. (NYSE:MSCI) ("MSCI" or the "Company") face up to 55% to 65% long-term downside risk, or $190.00 – $244.00 per share. Download or view the report by visiting www.SprucePointCap.com for additional information and exclusive updates.

    ***

    Spruce Point Report Overview

    MSCI, founded as Morgan Stanley Capital International, is a provider of decision support tools and solutions for the global investment community. The Company has four reporting segments: Index, Analytics, ESG and Climate, and All-Other Private Assets, which includes real estate analytics and the recently acquired Burgiss Group. MSCI's clients include asset owners (pensions, endowments, etc.), asset managers, financial intermediaries, wealth managers, real estate professionals and corporations. MSCI services 6,500 clients in over 95 countries. We believe each of MSCI's four segments is under pressure and that the Company is using a variety of aggressive financial reporting and accounting methods, along with expensive acquisitions, in an attempt to position itself for a changing investment landscape.

    The concerns we outline in our report include:

    • MSCI's core index business is under pressure, client Retention Rates are declining, executive leadership is being replaced, and reputational risks are rising. MSCI's core index business (58% of revenue) is no longer the driving force of innovation it once was. Through our research, we found that the Company understates the growing competition it faces from exchanges like Qontigo (owned by Deutsche Börse) and Nasdaq, which are increasing pressure on MSCI as they expand with new software and data solutions. We find that MSCI's Index segment Retention Rate, a measure of future revenue, has declined year-over-year in the past four consecutive quarters.



      In addition, MSCI also faces additional strain from its clients – such as BlackRock – that are under pressures of their own. For instance, approximately 10% and 17% of MSCI's total and Index segment revenue currently comes from BlackRock, which is embracing self-indexing, which reduces its need for MSCI's services. On top of that, BlackRock's U.S. market share of iShares ETFs is in perpetual decline, with analysts expecting Vanguard to soon become the new leader. As a result, it is no surprise that MSCI's fees linked to ETFs have also been in perpetual decline. In November, MSCI replaced its Head of Index, while BlackRock's Head of iShares departed last week. The combination of these events cast greater uncertainty over the relationship. On top of that, we believe MSCI's recent purchase of The Burgiss Group ("Burgiss") now puts it in greater competition with BlackRock, which could further pressure the relationship and fees.



      Other macro factors working against MSCI are higher interest rates and a strong dollar. Higher rates have caused total assets of AUM benchmarked to MSCI indices to decline almost double digits since 2021. In Q3'23, MSCI reported a decline in total clients and it has recently expanded risk factors that explain why client activity decreases. Absent punitive price increases, we estimate new recurring sales are down 40% in YTD'23. To win in "growth areas" such as thematic ETFs, MSCI's CEO recently referenced itself as having to turn into "a giant equity research shop." We believe the cost and complexity of transforming a large company such as MSCI with pronounced innovation challenges will be too difficult to surmount.



      Beyond competition and macro factors, MSCI's index franchise has also exposed itself to reputational risk in pursuit of fees by promoting Chinese indexed ETFs. As an example, Congress recently questioned MSCI's role in diverting capital towards Chinese companies included within the index that are possibly engaging in human rights violations.



    • MSCI's Analytics segment is also under pressure, anchored by increasingly commoditized solutions. The Analytics segment is ~26% of MSCI's revenue and ~18% of Adjusted EBITDA. As one former MSCI employee with 18 years of experience developing models said, "It's less about brain power – lots of physics PhDs in quant land – and more about the difficult and unglamorous job of sourcing, curating, managing and QA'ing data and the 24/7 operations to ensure updates are there every day, on time, for every asset class, for every model, for every client." Spruce Point believes artificial intelligence will automate and improve data management to further reduce competitive barriers and fees.



      In 2016, MSCI stated its intention to accelerate Analytics revenue growth rate from low to mid-single digits to the upper single digits over the long term. Seven years later, the growth rate has increased modestly to the 6% range (aided recently by punitive fee increases) but has averaged just 4.5% over the time period. Most of the segment was built with acquisitions dating 15-20 years ago and are still anchored by RiskMetrics and Barra Solutions. Not surprisingly, in a recent interview, an industry expert opined that MSCI's models are becoming commoditized. MSCI's results reinforce the reality that its Analytics segment is under increased pressures. For example, Spruce Point observes that MSCI recently experienced year-over-year declines in its organic sales growth, Adjusted EBITDA margin and client Retention Rate metrics. Client Retention Rate has fallen in three of the last four quarters while Adjusted EBITDA margin growth is declining after a period of strong expansion. Now, MSCI is referencing higher compensation costs across cost of revenue, selling and marketing and G&A, offset by lower R&D compensation expense after a period of cost capitalization. Our interpretation is that MSCI is likely experiencing wage pressures by retaining employees who may be looking to depart while customers churn.



    • Despite having been MSCI's recent growth driver, the Company's ESG and Climate segment is now beginning to struggle. Since 2020, MSCI's ESG and Climate Solutions business has been a growth engine with run rate revenue increasing from $138 million to $297 million and margins expanding from 20.5% to 34.8%. However, we believe the growth spurt is ending not only because of ESG pushback, regulatory uncertainty, and ESG's market underperformance but also because of MSCI-specific issues that have resulted in notable client retention challenges.



      In 2023, MSCI changed the way in which it describes the competitive advantages of its ESG and Climate business from having a "Unique Track Record" to simply having a "Long Track Record." To say that something is unique means that it is one of a kind or unlike anything else – but to say something has a long track record does not have the same notability. We view this modification in choice of words, along with MSCI's expanding disclosure of competitors such as Bloomberg and Moody's in its recent 10-K, as an indicator that its ESG and Climate business is coming under increased pressure. In addition, MSCI also added a pop-up box on its rating page to be used in sales lead generation before providing its public ratings. When we interviewed a former MSCI executive, we were told, "ESG competition is definitely increasing, especially Bloomberg. MSCI was one of the first, but that doesn't mean competitors aren't going to eat away at it. As early as 2023, people were leaving the ESG team. To grow, you have to have consistent sales. They were under target and didn't hit their goals. That business line was struggling." Lastly, we observe that MSCI is increasing its cost capitalization of development expense, which has the obvious effect of flattering margins.



    • The Private Assets segment, formed by the acquisitions of Real Capital Analytics ("RCA") in 2021 and The Burgiss Group ("Burgiss") in 2023, is fraught with continued challenges. MSCI's acquisition of RCA for $949 million was richly valued at approximately 13x and 48x run-rate revenue and EBITDA, respectively. We believe the RCA acquisition was littered with challenges and shows MSCI's propensity for aggressive revenue accounting. MSCI quickly marked down total clients from 2,000 to 1,600 after the acquisition but continued to claim that it had a high retention rate and that revenue should be considered recurring. MSCI and analysts talked up RCA's mid-to-high teens revenue growth and high and improving renewal rates. However, within a year after the acquisition, the evidence points to substantially lower revenue growth and MSCI stopped reporting RCA's Run-Rate revenue – a suspicious coincidence. A former MSCI employee commented, "The RCA deal was not the best or easiest transition. It was pretty disorganized. It was like a dumpster fire. There were a lot of mismanaged accounts. I don't think they did enough due diligence, like on their run rate, and what they are producing. There were a lot of outdated or accounts that weren't updated." Segment organic growth recently went negative while segment retention rate is negative on both a QoQ and YoY basis.



      In 2023, MSCI acquired the 66.4% of The Burgiss Group it didn't own at an implied 10x and 68x revenue and EBITDA, respectively. Spruce Point believes that at best Burgiss was breakeven and at worst it was losing money and it has struggled to grow its client base in the past four years. We have also identified evidence of weak accounting and/or financial controls as suggested by MSCI electing to report Burgiss' results on a three-month lag. Lastly, Burgiss competes with eFront, a company owned by BlackRock, which raises the risk of greater friction with its largest customer.



    • MSCI has exhibited an alarming pattern of nepotism-like acquisitions and alliances with Morgan Stanley and MSCI-related alums. MSCI was formerly Morgan Stanley Capital International, so there is no hiding the fact that its roots originated at Morgan Stanley. MSCI IPO'ed in 2007, and Morgan Stanley was its lead underwriter.



      Unsurprisingly, we find that MSCI has recently engaged in a suspicious pattern of acquisitions and alliances that benefit Morgan Stanley and well-known MSCI alums. Overall, we question whether these deals are in the best interest of MSCI shareholders or are being done simply to benefit the former colleagues in the circle of MSCI Chairman and CEO Henry Fernandez. We refer to this as nepotism-like dealing and we find many recent examples.
         

    (1)

    In 2021, Mr. Fernandez became Lead Independent Director of Royalty Pharma plc (NYSE:RPRX), which receives fees from MSCI for advice on science-based thematic ETFs. Morgan Stanley is also a top shareholder of RPRX. Mr. Fernandez's son became employed at RPRX around the time of his father's appointment.

         

     

         

    (2)

    In 2022, MSCI struck an alliance with Menai Financial Group, a company in the digital asset space intended to provide MSCI advice, with undisclosed deal terms. Menai was founded by Zoe Cruz, former co-President of Morgan Stanley.

         

     

         

    (3)

    When it comes to the recent Burgiss transaction in 2023, Jay McNamara was President of Burgiss and was formerly an Executive Committee member at MSCI. MSCI hasn't disclosed how much Mr. McNamara personally benefited from the transaction, which, as we pointed out, was at a rich valuation.

         

     

         

    (4)

    Lastly, in December 2023, MSCI acquired Fabric, a wealth technology platform for an undisclosed amount. Our research suggests that Fabric had limited headcount and web traffic growth. Fabric's co-founder was formerly Morgan Stanley's first Chief Risk Officer.

    • MSCI is shifting attention to Adjusted EPS while cash flow and dividend growth struggles and aggressive accounting decisions flatter revenue and costs. MSCI ceased providing margin guidance and dismissed margins as not meaningful while putting greater emphasis on Adjusted EPS. In 2022, MSCI changed management's long-term compensation targets to cumulative Adjusted EPS and revenue despite not providing investors with guidance on either metric. We believe MSCI uses a variety of dubious adjustments to bolster its Adjusted EPS.



      By our estimate, Adjusted EPS was -28% and -13% below MSCI's reported results in 2021 and 2022, respectively. MSCI's revenue in recent quarters has been flattered with non-recurring revenue, some of which is related to prior periods. On the cost side, MSCI's segment reporting gives management the potential for wide latitude to manipulate margins to its benefit. We observe that it can allocate costs by segment using different methods without incurring "arm's length" charges. Lastly, MSCI appears to be making greater use of capitalized development costs that are added to the balance sheet, amortized to the income statement and conveniently ignored as non-cash add-backs. MSCI should disclose how much costs are being capitalized per segment and the exact effect on margins. As of its last financial update, MSCI has not been able to increase cash flow guidance even as operating costs rise and after tapping the revolver for additional liquidity to complete the Burgiss acquisition (despite enough cash on hand and cash flow). Moreover, MSCI's dividend growth has averaged 27.9% from inception in 2014 through 2023 but its recent increase was 10.4%, the lowest growth rate ever. We believe management may be signaling cash flow growth challenges ahead with these actions.



    • In the context of our findings about aggressive accounting decisions and lapses in acquisition due diligence, we have grave concerns about Board, audit, and accounting oversight at MSCI. We are alarmed to see that MSCI's Chief Accounting Officer (CAO) resigned on August 18, 2023. As of this report, MSCI has not named a successor to the CAO role and it does not have a Global Controller, which should be a significant red flag for investors. In addition, we question the fitness of MSCI's Director Catherine Kinney who has served on the Board since 2009. Ms. Kinney has not only been involved with SolarWinds (NYSE:SWI) since its IPO, but most concerning, she served as the Chair of the Nominating and Governance Committee which was responsible for firm-wide risk management. She was also a member of the Audit Committee. Spruce Point finds it alarming that the SEC recently charged SolarWinds with fraud for internal control failures during Ms. Kinney's directorship. Also of concern is the fact that MSCI claims its Audit Committee "Financial Expert" is Robert Ashe. Mr. Ashe has primarily served in operational and business management roles during his career with a brief stint as a public company CFO of Cognos over 20 years ago. While he was CEO of Cognos, the Company delayed its 10-K/Q as the SEC reviewed its revenue recognition policies. He has a CPA in Canada, but MSCI reports in U.S. GAAP. If the weakness with MSCI's Board and accounting oversight is not evident enough, we also find evidence that MSCI's PwC Audit Engagement Partner is not a financial services specialist. Her other audit clients are primarily chemical and shipping companies, and her LinkedIn biography references the title "Industrial Products Assurance Partner."



    • The bottom line is that an investment in MSCI presents a poor risk/reward for investors, given the Company's high expectations, rich valuation and apparent struggles. Analysts are bullish on MSCI, however, the average sell-side consensus price target is $554/share, representing just 2.6% upside potential. Spruce Point believes the current sell-side promoters need to refresh their thinking about MSCI and the sustainability of its growth and margins, especially in "faster growth" segment areas in ESG and Climate and Private Assets. We believe it is easy to dismiss much of the bull case narrative with some simple channel checks, a close forensic review of MSCI's financials and by speaking with former employees. Specifically, we believe analysts and investors need to rethink the sustainability of MSCI's high client retention in a changing competitive landscape and its capital allocation policies. We believe management is showing poor discipline with acquisitions, while deploying too much capital to share repurchases with its stock trading at an industry-high multiple of 17x and 29x 2024E revenue and Adjusted EBITDA. Investors would be better served with a higher dividend rather than allowing management to essentially buy its way toward handsome long-term bonuses tied to Adjusted EPS. MSCI's leverage is now at a decade high at approximately 3x Net Debt / EBITDA which we believe is at the worst time as client Retention Rates decline. By conducting a realistic sum-of-parts valuation of MSCI's business segments, we estimate 55% - 65% ($190.00 – $244.00 per share) downside risk and expect MSCI to underperform the S&P 500 and its own relevant benchmark indices.

    ***

    Please note that the items summarized in this press release are expanded upon and supported with data, public filings and records, and images in Spruce Point's full report. As a reminder, our full report, along with its investment disclaimers, can be downloaded and viewed at www.SprucePointCap.com.

    As disclosed, Spruce Point and/or its clients have a short position in MSCI Inc. and owns derivative securities that stand to net benefit if its share price falls.

    About Spruce Point

    Spruce Point Capital Management, LLC is a forensic fundamentally-oriented investment manager that focuses on short-selling, value and special situation investment opportunities.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240117565436/en/

    Get the next $MSCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MSCI
    $RPRX
    $SWI

    CompanyDatePrice TargetRatingAnalyst
    MSCI Inc.
    $MSCI
    3/17/2026$710.00Outperform → Strong Buy
    Raymond James
    MSCI Inc.
    $MSCI
    2/17/2026$700.00Buy
    BofA Securities
    Royalty Pharma plc
    $RPRX
    1/30/2026$49.00Neutral → Buy
    UBS
    MSCI Inc.
    $MSCI
    10/1/2025$650.00Buy
    Seaport Research Partners
    Royalty Pharma plc
    $RPRX
    9/30/2025$42.00Buy
    Goldman
    MSCI Inc.
    $MSCI
    7/25/2025$650.00Mkt Perform → Outperform
    Raymond James
    Royalty Pharma plc
    $RPRX
    5/16/2025$51.00Overweight
    Morgan Stanley
    MSCI Inc.
    $MSCI
    4/10/2025$585.00Neutral
    BofA Securities
    More analyst ratings

    $MSCI
    $RPRX
    $SWI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Coyne Terrance P.

    4 - Royalty Pharma plc (0001802768) (Issuer)

    4/2/26 5:58:57 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bassler Bonnie L

    4 - Royalty Pharma plc (0001802768) (Issuer)

    3/31/26 4:09:28 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Coyne Terrance P.

    4 - Royalty Pharma plc (0001802768) (Issuer)

    3/25/26 5:05:22 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MSCI
    $RPRX
    $SWI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MSCI upgraded by Raymond James with a new price target

    Raymond James upgraded MSCI from Outperform to Strong Buy and set a new price target of $710.00

    3/17/26 7:54:49 AM ET
    $MSCI
    Real Estate

    BofA Securities resumed coverage on MSCI with a new price target

    BofA Securities resumed coverage of MSCI with a rating of Buy and set a new price target of $700.00

    2/17/26 7:31:33 AM ET
    $MSCI
    Real Estate

    Royalty Pharma upgraded by UBS with a new price target

    UBS upgraded Royalty Pharma from Neutral to Buy and set a new price target of $49.00

    1/30/26 6:41:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MSCI
    $RPRX
    $SWI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MSCI to Reclassify the MSCI Greece Indexes from Emerging Market to Developed Market status

    MSCI Inc. (NYSE:MSCI) announced that the MSCI Greece Indexes will be reclassified from Emerging Market to Developed Market status in one step coinciding with the May 2027 Index Review. On January 26, 2026, MSCI launched a consultation with international institutional investors on a Market Reclassification Proposal for the MSCI Greece Indexes. MSCI received feedback from a large number of global market participants, including asset owners, asset managers and broker dealers. The majority of participants in the consultation favored the proposed reclassification. "Greece's path from Emerging Market back to Developed Market status reflects both the progress achieved by the Greek market autho

    3/31/26 5:59:00 PM ET
    $MSCI
    Real Estate

    Accelerant Completes CFO Transition

    Linda S. Huber Appointed Chief Financial Officer Accelerant (NYSE:ARX), the data-driven risk exchange platform transforming the specialty insurance marketplace through the Accelerant Risk Exchange, today appointed Linda S. Huber as Chief Financial Officer following the previously announced CFO transition. Huber brings significant financial services industry experience to the role, including nearly two decades as a public company CFO. Huber will lead Accelerant's global finance organization, including accounting, financial planning and analysis, treasury, and tax, and report to Jeff Radke, Accelerant's Chief Executive Officer. "We're excited to welcome Linda to the team," said Radke. "

    3/31/26 4:05:00 PM ET
    $ARX
    $FDS
    $MCO
    Specialty Insurers
    Finance
    Computer Software: Programming Data Processing
    Technology

    Syntax Data Collaborates with MSCI to Bring Global ADR Indexes to Syntax Direct Platform

    Partnership enables financial advisers to build customized international portfolios without leaving U.S. exchanges Syntax Data, a financial data and technology provider offering data-optimized index solutions, today announced a partnership with MSCI Inc. (NYSE:MSCI) to offer a range of MSCI indexes on the Syntax Direct platform: a forward-looking index development tool that revolutionizes the rapidly growing direct-to-index investment process. As part of this strategic collaboration, MSCI will help Syntax expand into the independent RIA channel by helping financial advisers gain access to an expanded set of ADR index universes while also providing distribution support for the wealth man

    3/31/26 7:03:00 AM ET
    $MSCI
    Real Estate

    $MSCI
    $RPRX
    $SWI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ashe Robert G. bought $1,999,556 worth of shares (3,681 units at $543.21) (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    2/20/26 4:04:06 PM ET
    $MSCI
    Real Estate

    Chairman and CEO Fernandez Henry A bought $3,560,239 worth of shares (6,800 units at $523.56), increasing direct ownership by 0.46% to 1,493,847 units (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    2/17/26 6:02:45 PM ET
    $MSCI
    Real Estate

    Chairman and CEO Fernandez Henry A bought $6,701,732 worth of shares (12,500 units at $536.14), increasing direct ownership by 0.69% to 1,487,047 units (SEC Form 4)

    4 - MSCI Inc. (0001408198) (Issuer)

    12/9/25 6:38:10 AM ET
    $MSCI
    Real Estate

    $MSCI
    $RPRX
    $SWI
    SEC Filings

    View All

    SEC Form 13F-NT filed by Royalty Pharma plc

    13F-NT - Royalty Pharma plc (0001802768) (Filer)

    4/1/26 4:41:34 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MSCI Inc. filed SEC Form 8-K: Leadership Update

    8-K - MSCI Inc. (0001408198) (Filer)

    3/31/26 4:14:09 PM ET
    $MSCI
    Real Estate

    Amendment: SEC Form SCHEDULE 13G/A filed by MSCI Inc.

    SCHEDULE 13G/A - MSCI Inc. (0001408198) (Subject)

    3/27/26 10:50:14 AM ET
    $MSCI
    Real Estate

    $MSCI
    $RPRX
    $SWI
    Leadership Updates

    Live Leadership Updates

    View All

    Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

    NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. "Lucas's appointment marks a significant step in our commitment to implementing cutting‑edge technology across our platform," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "By incorporating intelligent automation, advanced analytics and AI-driven decision support, we are strengthening how we evaluate and invest in royalties and support our partners. Luc

    3/23/26 7:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Announces Expansion of Leadership Team

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. "We are thrilled that Greg will join Royalty Pharma and strengthen our leadership team," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "Greg brings tremendous experience advising healthcare companies on capital raising, strategy, and mergers and acquisitions and he will be a critical addition t

    3/17/26 4:01:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

    NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking. Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2025, the out-licensing of Chinese medicines alone comprised over $130 billion of announced transaction value, up from approximately $14 billion in 2021, as multinational pharmaceutical companies increasingly recognized the va

    3/2/26 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MSCI
    $RPRX
    $SWI
    Financials

    Live finance-specific insights

    View All

    Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

    NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune‑mediated diseases. "We are delighted to collaborate with Johnson & Johnson on the clinical development of JNJ-4804," said Pablo Legorreta, Chief Executive Officer and Chairman of the

    3/30/26 7:15:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma Reports Q4 and Full Year 2025 Results

    Portfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in Q4 2025 and $2,490 million for FY 2025Full year 2026 guidance: Portfolio Receipts expected to be $3,275 million to $3,425 million NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced full year 2026 guidance for Portfolio Receipts. "We had one of the most remarkable years in Royalty Pharma's history in 2025," said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chai

    2/11/26 7:00:00 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996,

    1/20/26 4:15:00 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MSCI
    $RPRX
    $SWI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

    SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

    11/8/24 3:15:49 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

    SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

    7/29/24 4:30:11 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MSCI Inc. (Amendment)

    SC 13G/A - MSCI Inc. (0001408198) (Subject)

    2/13/24 5:09:39 PM ET
    $MSCI
    Real Estate